Court Blocks Tennessee From Dictating Employer Pharmacy Benefit Design

Why It Matters

The ruling preserves federal uniformity for self‑funded plans, allowing employers to manage prescription costs without state interference, a critical advantage for multi‑state businesses.

Key Takeaways

• Sixth Circuit rules Tennessee PBM laws preempted by ERISA.
• Employers keep authority to design self‑funded pharmacy networks.
• State bans on differential copays deemed beyond ERISA's reach.
• Multi‑state firms avoid fragmented rules thanks to uniform federal preemption.
• HR teams can continue using incentives to steer prescription costs.

Pulse Analysis

The U.S. Court of Appeals for the Sixth Circuit reaffirmed a core tenet of the Employee Retirement Income Security Act: states cannot dictate the design of self‑funded health‑plan pharmacy benefits. By striking down Tennessee’s recent pharmacy‑benefit‑manager statutes, the court emphasized that ERISA preempts any state rule that forces employers into a specific network structure or bans differential copays. The decision builds on prior rulings such as Rutledge v. PCMA, but draws a clearer line where state regulation intrudes on plan architecture rather than merely controlling costs.

For employers, especially those with multi‑state workforces, the ruling restores broad discretion over pharmacy network composition, tiered copayment schedules, and the use of employer‑owned pharmacies. Companies can again exclude underperforming pharmacies, negotiate tiered pricing, and offer lower copays to steer members toward cost‑effective options without fearing state enforcement. PBMs remain free to tailor networks to the sponsor’s risk‑management goals, preserving the uniformity ERISA was designed to guarantee. HR leaders can therefore continue leveraging financial incentives as a tool for managing prescription spend while maintaining compliance with federal law.

While Tennessee’s attempt to regulate PBMs may reappear in a more limited form, the Sixth Circuit’s opinion signals that any future state legislation must stay within the narrow bounds of cost‑control measures and avoid reshaping benefit design. Employers should audit their pharmacy‑benefit arrangements for any provisions that could be construed as state‑mandated and document the ERISA basis for their network decisions. Legal counsel and benefits teams are advised to monitor pending federal guidance, as the balance between state consumer‑protection goals and federal preemption will shape the next wave of pharmacy‑benefit reforms.